OTCMKTS:IMNPQ Immune Pharmaceuticals (IMNPQ) Stock Price, News & Analysis $0.0010 0.00 (0.00%) As of 08/17/2022 Add Compare Share Share Stock Analysis Stock Analysis About Immune Pharmaceuticals Stock (OTCMKTS:IMNPQ) Get Immune Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0001▼$0.0070VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Immune Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of antibody-based therapies for immune-mediated and inflammatory diseases. The company’s research platform centers on novel monoclonal antibodies designed to modulate key pathways in chronic inflammatory conditions, including dermatological and gastrointestinal disorders. Immune Pharmaceuticals’ lead product candidate is bertilimumab, a fully human monoclonal antibody targeting eotaxin-1, which has been studied in conditions such as bullous pemphigoid and ulcerative colitis. The company also holds rights to itolizumab, an anti-CD6 antibody licensed from Biocon, with potential applications in psoriasis, atopic dermatitis and other T-cell driven diseases. These programs are supported by preclinical and clinical data aimed at demonstrating safety and efficacy across a range of indications. Headquartered in New York City, Immune Pharmaceuticals advances its pipeline through a combination of internal capabilities and strategic partnerships. The company collaborates with academic institutions and development partners across North America, Europe and Asia to conduct clinical trials and scale manufacturing. By leveraging targeted immunology expertise and global regulatory experience, Immune Pharmaceuticals seeks to address unmet needs in rare and chronic inflammatory disorders.AI Generated. May Contain Errors. Read More Receive IMNPQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMNPQ Stock News HeadlinesImmune system breakthrough wins Nobel medicine prize for US, Japan scientistsOctober 7, 2025 | msn.comRegeneron's immune disorder therapy improves daily functions in trialAugust 26, 2025 | msn.comNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new form of AI called Sovereign AI could trigger a $248 trillion economic disruption before the end of 2026. Chaikin, whose system flagged Nvidia as bullish back in 2014 before its 52-fold rise, warns this shift could reshape the entire AI industry and create what he calls the Great Wealth Rotation. America's first Sovereign AI factory is set to open this year, and Chaikin has identified one company positioned to benefit.September 20 at 1:00 AM | Chaikin Analytics (Ad)Piper Sandler Sticks to Its Buy Rating for Immunome (IMNM)November 14, 2024 | markets.businessinsider.comDistinct immune profiles linked to adverse reactions from immunotherapyOctober 16, 2024 | msn.comFact Check: Fact Check: German study did not find mRNA shots ‘eat away’ at children’s immune systemsSeptember 11, 2024 | reuters.comThese Stocks Are Moving the Most Today: Alpine Immune, Vertex, Robinhood, Regeneron, Costco, Constellation Brands, CarMax, and MoreApril 11, 2024 | msn.comVertex Pharmaceuticals to Buy Alpine Immune Sciences for $4.9 BillionApril 10, 2024 | money.usnews.comSee More Headlines IMNPQ Stock Analysis - Frequently Asked Questions How have IMNPQ shares performed this year? Immune Pharmaceuticals' stock was trading at $0.0010 on January 1st, 2026. Since then, IMNPQ stock has increased by 0.0% and is now trading at $0.0010. How do I buy shares of Immune Pharmaceuticals? Shares of IMNPQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IMNPQ CIK1208261 Webwww.immunepharma.com Phone(201) 464-2677Fax917-398-1915Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:IMNPQ) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredElon Musk to Trigger Next AI Wave on November 11th?Jeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredNo Wallstreet. No Advisor. No Problem.Savings accounts pay just 0.58 percent interest. Andy Howard, co-founder of Meridian Capital, says liquidity p...Awesomely | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immune Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
